).
Identifying pregnancies at increased risk for aneuploidy has been a part of the practice of maternal-fetal medicine for several decades. Originally, women were identified based on maternal age alone and given the option of diagnostic testing via chorionic villus sampling (CVS) or amniocentesis to determine the fetal karyotype. Recently, maternal serum screening tests, with or without ultrasound findings, were developed for use in the general obstetrical population to identify at-risk pregnancies.
1,2 Since CVS and amniocentesis carry a risk for miscarriage, research has continued to pursue other means of obtaining the fetal genetic complement.
Recently, three separate multicenter trials of noninvasive prenatal testing (NIPT) showed that analyzing cell-free DNA in the maternal circulation results in a highly sensitive and specific testing option for fetal aneuploidy, with 98 to 100% detection rate at < 0.3% false-positive rate for Down syndrome and 97 to 100% detection rate at < 0.28% false-positive rate for trisomy 18. [3] [4] [5] [6] The detection rate for trisomy 13 varied more widely across studies, ranging from 79 to 92% with < 1% false-positive rate.
4,6
Advances in prenatal screening for aneuploidy have led to a decrease in invasive testing and an increase in screening in the Keywords ► noninvasive prenatal testing ► NIPT ► cell-free DNA ► genetic screening
Abstract
Objective Noninvasive prenatal testing (NIPT) via cell-free fetal DNA in the maternal circulation is a highly sensitive and specific new testing option. The objective of this study was to determine the impact of NIPT on the uptake of first trimester screening (FTS) and invasive genetic testing. Study Design Uptake of prenatal testing was investigated in women referred for advanced maternal age or abnormal screening to the University of Texas Health Maternal-Fetal Medicine Clinics in Houston. Patients who presented from August to November 2011, before clinical introduction of NIPT, were compared with patients who presented from March to June 2012, after its introduction. Results In patients referred between 14 and 22 weeks gestational age, invasive genetic testing was significantly reduced following the introduction of NIPT (35.4 vs. 17.9%, p < 0.05). For patients referred at < 14 weeks gestational age, FTS was significantly reduced with NIPT introduction (89.1 vs. 59.1%, p < 0.05); however, invasive genetic testing was not significantly different (20.0 vs. 14.0%, p > 0.05). Conclusion NIPT has made an impact on the practice of maternal-fetal medicine by significantly decreasing the number of second trimester diagnostic tests performed. In addition, patients interested in early screening information appear to prefer the higher sensitivity and specificity of NIPT.
at-risk population. Overall, NIPT was chosen by 31.6% of patients who received genetic counseling in the first trimester and by 17.0% in the second trimester. Before the implementation of NIPT, 89.1% (n ¼ 147) of patients referred before 14 weeks elected to pursue combined FTS. The uptake of FTS fell significantly to 59.1% (n ¼ 114) following the introduction of NIPT (p < 0.05; ►Fig. 1). The uptake of invasive genetic testing by first trimester patients was not significantly different with 20.0% (n ¼ 33) pursuing CVS or amniocentesis before NIPT and a 14.0% (n ¼ 27) uptake following the availability of NIPT (p > 0.05; ►Fig. 2). There was, however, a significant decrease in the uptake of invasive diagnostic testing for those patients receiving genetic counseling between 14 and 22 weeks with 35.4% (n ¼ 104) of patients before NIPT electing amniocentesis and only 17.9% (n ¼ 59) of patients electing amniocentesis after the availability of NIPT (p < 0.05; ►Fig. 3). Although there was a decrease in the uptake of amniocentesis and an increase in uptake of NIPT, overall, there was no difference in the number of women choosing no further genetic testing following genetic counseling after the introduction of NIPT compared with before its introduction (42.4 vs. 41.4%; p < 0.05). Finally, per capita testing reimbursement was 15.77% less following the introduction of NIPT ($101.32 vs. $85.34).
Comment Principal Findings
NIPT has already made an impact on our practice of maternal-fetal medicine by significantly decreasing the number of second trimester diagnostic tests performed. This finding was also observed by another group when only women with a positive aneuploidy screening result were studied. 10 Patients interested in early screening information appear to prefer the higher sensitivity and specificity of NIPT to combined FTS. Early diagnostic information seekers, however, appear to remain most comfortable with CVS. Per capita testing reimbursement fell by almost 16%. It is important to note that it is our practice to perform an ultrasound for viability at the time of NIPT testing to ensure that NIPT is indicated. Per capita testing reimbursement could fall even more sharply in units that have not adopted this practice. For example, if our practice did not include a viability ultrasound before blood draw for NIPT in the first trimester, a per capita drop of 35.37% would have occurred ($101.32 vs. $65.48). Maternal-Fetal Medicine clinics will need to take into consideration decreased uptake of second trimester diagnostic tests and the utilization of viability ultrasounds when evaluating their business model.
In contrast with the recent findings of Chetty et al, 10 our study did not identify a decline in women choosing no further genetic testing following the introduction of NIPT. This may be due to the many differences in the patient populations studied. Our patients were identified by referrals for genetic counseling for both advanced maternal age and positive Fig. 1 The uptake of FTS for patients receiving genetic counseling at < 14 weeks gestational age before and after the availability of NIPT. Before the implementation of NIPT, 89.1% (n ¼ 147) of patients referred at < 14 weeks elected to pursue FTS. This uptake fell significantly to 59.1% (n ¼ 114) following the introduction of NIPT (p < 0.05; *). FTS, first trimester screening; NIPT, noninvasive prenatal testing.
maternal serum screening in parallel to recent practice guidelines developed jointly by the American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee for NIPT. 11 Consequently, our patient population was older.
Furthermore, they also had a different ethnic makeup and payer mix.
Strengths and Weaknesses
The strengths of our study include the evaluation of the immediate impact of this new genetic screening test in a large number of ethnically diverse patients from a single urban referral area with a uniform protocol for offering NIPT. The protocol was in accordance with recently published practice guidelines. 11, 12 Weaknesses include the fact that the study only evaluates the immediate impact of the introduction of NIPT. These data would be expected to change with increased knowledge and education about NIPT by both patients and referring physicians. Finally, there are regional differences in uptake of prenatal genetic screening and invasive diagnostic testing. Our results may be different than those found in other regions, as well as more rural areas, of the country.
Implications for Clinicians
It is imperative that clinicians educate themselves about NIPT, as its introduction is transforming prenatal testing. Taking a family history and reviewing patient records to determine that a patient is an appropriate candidate, and pretest counseling to ensure that patients understand the implication of a positive and negative result is essential.
12 Fig. 2 The uptake of invasive diagnostic testing for patients receiving genetic counseling at < 14 weeks gestational age before and after the availability of NIPT. The uptake of invasive genetic testing by first trimester patients was not significantly different with 20.0% (n ¼ 33) pursuing CVS or amniocentesis before NIPT and a 14.0% (n ¼ 27) uptake following the availability of NIPT (p > 0.05). CVS, chorionic villus sampling; NIPT, noninvasive prenatal testing. Fig. 3 The uptake of invasive diagnostic testing for patients receiving genetic counseling between 14 and 22 weeks before and after the availability of NIPT. There was a significant decrease in the uptake of invasive diagnostic testing for those patients receiving genetic counseling between 14 and 22 weeks with 35.4% (n ¼ 104) of patients before NIPT electing amniocentesis and only 17.9% (n ¼ 59) of patients electing amniocentesis after the availability of NIPT (p < 0.05; *). NIPT, noninvasive prenatal testing.
